Yahoo Web Search

Search results

1. • 

     Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

     Zacks via Yahoo Finance· 2 years ago

     Biogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat...

2. • 

     Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

     Zacks via Yahoo Finance· 2 years ago

     Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in...

3. • 

     Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?

     Zacks via Yahoo Finance· 2 years ago

     Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are...

4. • 

     Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

     Zacks via Yahoo Finance· 2 years ago

     Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages...

5. • 

     What's Behind 2020's Medicare Part B Premium Sticker Shock?

     SmartAsset via Yahoo Finance· 1 year ago

     The surprisingly big jump in Medicare Part B premiums for 2022 reflects the sky-high cost of a...

6. • 

     Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

     Zacks via Yahoo Finance· 3 months ago

     Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The...

7. • Alzheimer's volunteer urges Medicare, Medicaid to approve new drug

     The Moultrie Observer, Ga. via Yahoo News· 1 year ago

     Mar. 23—MOULTRIE, Ga. — Alzheimer's disease and other dementias are devastating. On Jan. 6, the U.S. Food and Drug Administration approved a medication that offers hope to those with Alzheimer's ...

8. • 

     Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

     Zacks via Yahoo Finance· 1 year ago

     FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental...

9. • 

     Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers

     Benzinga via Yahoo Finance· 1 year ago

     Earlier today, MorphoSys AG (NASDAQ: MOR) and its partner Roche Holdings AG (OTC: RHHBY) reported...

10. • 

      Biogen stock explodes higher after potential 'mega blockbuster' Alzheimer's drug study

      Yahoo Finance via AOL· 2 years ago

      Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a...